Malignant Pleural Effusion Market Report 2026

The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.73 billion in 2025 to $5.05 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing incidence of metastatic cancers, limited curative treatment options, reliance on repeated thoracentesis for symptom control, growing hospital-based cancer care, gradual adoption of pleurodesis techniques.

The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.52 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising cancer prevalence worldwide, advancements in pleural catheter technologies, increasing emphasis on outpatient and home-based care, improved diagnostic imaging accuracy, growing demand for quality-of-life-focused treatments. Major trends in the forecast period include increasing use of indwelling pleural catheters for long-term management, rising preference for minimally invasive pleural interventions, growing integration of systemic cancer therapies in mpe management, higher focus on symptom relief and palliative care approaches, expansion of imaging-guided diagnostic and therapeutic procedures.

The increasing incidence of lung cancer is expected to drive the growth of the malignant pleural effusion market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, which can form tumors and disrupt normal lung function. The rise in lung cancer cases is largely attributed to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, induces genetic mutations, and promotes the unchecked growth of cancerous cells, substantially increasing the risk of developing the disease. Malignant pleural effusion reflects advanced lung cancer progression by enabling tumor spread within the pleural cavity, resulting in impaired respiratory function and a poorer prognosis. For example, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organization, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Consequently, the rising incidence of lung cancer is fueling the growth of the malignant pleural effusion market.

The expanding healthcare infrastructure is anticipated to drive the growth of the malignant pleural effusion market in the coming years. Healthcare infrastructure encompasses the physical, technological, and organizational frameworks necessary for delivering healthcare services, including hospitals, clinics, medical equipment, IT systems, and workforce. The development of healthcare infrastructure is linked to the need for improved disease management, all of which contribute to better healthcare accessibility, efficiency, and quality of care. Enhanced healthcare infrastructure improves the diagnosis, treatment, and management of malignant pleural effusion by providing access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately leading to improved patient outcomes. For example, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States rose by 0.591% from the previous year, increasing from 6,093 to 6,129. Therefore, the expanding healthcare infrastructure is fueling the growth of the malignant pleural effusion market.

Major companies operating in the malignant pleural effusion market are concentrating on developing innovative products such as fully implantable automatic fluid-shunt devices to enhance patient comfort and minimize hospital visits. A fully implantable automatic fluid-shunt device is a medical device placed inside the body that automatically drains excess pleural fluid from the lungs into the abdomen or another area, helping alleviate symptoms of breathlessness, reduce the frequency of hospital procedures, and improve patient quality of life. For example, in October 2023, Pleural Dynamics, a US-based medical device company, introduced the ACES Automatic Continuous Effusion Shunt System. This device features a resilient flexible pump chamber implanted under the skin between the ribs, with one catheter positioned in the pleural space and another in the peritoneal space. As the patient breathes, the internal pump extension is compressed and decompressed between adjacent ribs, moving fluid from the pleural cavity to the abdomen where it is reabsorbed; the system also permits manual activation through an external compression extension. Key features include a fully implantable design, no external drainage tubing or suction bottles, breathing-powered automatic pumping function, minimal hospital stay for implantation, and continuous symptom relief from recurrent effusions.

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc.

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the malignant pleural effusion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the malignant pleural effusion market by increasing the costs of imported pleural catheters, drainage systems, and diagnostic equipment. Treatment segments such as indwelling pleural catheters and imaging-based diagnostics are most affected, particularly in regions dependent on medical device imports like asia-pacific and parts of europe. These cost pressures may slow adoption in price-sensitive healthcare systems. However, tariffs have also encouraged local manufacturing and regional sourcing, supporting supply chain resilience.

The malignant pleural effusion market research report is one of a series of new reports that provides malignant pleural effusion market statistics, including malignant pleural effusion industry global market size, regional shares, competitors with a malignant pleural effusion market share, detailed malignant pleural effusion market segments, market trends and opportunities, and any further data you may need to thrive in the malignant pleural effusion industry. This malignant pleural effusion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Malignant pleural effusion (MPE) is the buildup of fluid in the pleural space caused by the presence of cancer cells, usually as a result of metastatic disease. This condition arises when cancer spreads to the pleura, the thin membrane surrounding the lungs, causing increased vascular permeability and reduced lymphatic drainage.

The primary treatment approaches for malignant pleural effusion include systemic therapy, therapeutic thoracentesis, thoracic drainage with pleurodesis, and placement of an indwelling pleural catheter. Systemic therapy involves administering cancer treatment through the bloodstream to target and destroy cancer cells throughout the body. Diagnosis is made using several methods, such as pleural fluid cytology, immunohistochemical analysis, imaging tests, pleural thoracentesis, pleuroscopy, and pleural biopsy. These treatments and diagnostic techniques are employed by various end users, including hospitals, ambulatory clinics, and other healthcare facilities.

The malignant pleural effusion market consists of revenues earned by entities by providing services such as biopsy and cytology testing, chemotherapy and targeted therapy, and pleurodesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant pleural effusion market also includes sales of chest drainage systems, pleural access kits, and imaging-guided drainage equipment, and thoracentesis devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.